Practical recommendations for the use of PARP inhibitors in the treatment of ovarian cancer

Czech version

Authors: D. Cibula; R. Kocián
Authors‘ workplace: Klinika gynekologie, porodnictví a neonatologie 1. LF UK a VFN v Praze
Published in: Klin Onkol 2025; 38(3): 218-223
Category: Short Communication
doi: https://doi.org/10.48095/ccko2025218

Overview

Background: There is no doubt that PARP inhibitors (PARPi) have significantly improved the prognosis of patients with advanced-stage ovarian cancer. In the history of treatment for this disease, their impact is second only to the introduction of platinum-based chemotherapy. As with any new therapeutic modality, integrating PARPi into routine clinical practice is a complex process. In the Czech Republic, some agents, combinations, or indications are not reimbursed, and indication criteria often require several conditions to be met simultaneously. These factors may lead to uncertainties in the practical use of PARPi. Aim: This article aims to highlight and discuss areas where such uncertainties may arise in clinical practice.

Keywords:

PARP inhibitors – ovarian cancer – indication criteria – PARPi

Sources

1. Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science 2017; 355 (6330): 1152–1158. doi: 10.1126/science.aam7344.

2. D’Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair 2018; 71: 172–176. doi: 10.1016/j.dnarep.2018.08.021.

3. Bryant HE, Schultz N, Thomas HD et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005; 434 (7035): 913–917. doi: 10.1038/nature03443.

4. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434 (7035): 917–921. doi: 10.1038/nature03445.

5. Ledermann JA, Matias-Guiu X, Amant F et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol 2024; 35 (3): 248–266. doi: 10.1016/j.annonc.2023.11.015.

6. Moore K, Colombo N, Scambia G et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018; 379 (26): 2495–2505. doi: 10.1056/NEJMoa1810858.

7. Gonzalez-Martin A, Pothuri B, Vergote I et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019; 381 (25): 2391–2402. doi: 10.1056/NEJMoa1910962.

8. Ray-Coquard I, Pautier P, Pignata S et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019; 381 (25): 2416–2428. doi: 10.1056/NEJMoa1911361.

9. DiSilvestro P, Banerjee S, Colombo N et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol 2023; 41 (3): 609–617. doi: 10.1200/JCO.22.01549.

10. Gonzalez-Martin A, Pothuri B, Vergote I et al. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer 2023; 189: 112908. doi: 10.1016/j.ejca.2023.04.024.

11. Monk BJ, Barretina-Ginesta MP, Pothuri B et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol 2024; 35 (11): 981–992. doi: 10.1016/j.annonc.2024.08.2241.

12. Ray-Coquard I, Leary A, Pignata S et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol 2023; 34 (8): 681–692. doi: 10.1016/j.annonc.2023.05.005.

13. Hockings M, Miller RE. The role of PARP inhibitor combination therapy in ovarian cancer. Ther Adv Med Oncol 2023; 15: 17588359231173183. doi: 10.1177/17588359231173183.

14. Du Bois A, Sehouli J, Vergote I et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III/ENGOT-ov20. J Clin Oncol 2020; 38 (Suppl 15): 6000. doi: 10.1200/JCO.2020.38.15_suppl.6000.

15. Gonzalez-Martin A, Harter P, Leary A et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34 (10): 833–848. doi: 10.1016/ j.annonc.2023.07.011.

16. Poveda A, Floquet A, Ledermann JA et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021; 22 (5): 620–631. doi: 10.1016/S1470-2045 (21) 00073-5.

17. Matulonis U, Herrstedt J, Oza A et al. Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer (LBA 6). Gynecol Oncol 2023; 176 (Suppl 1): S31–S32.

18. Friedlander M, Matulonis U, Gourley C et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 2018; 119 (9): 1075–1085. doi: 10.1038/s41416-018-0271-y.

19. Zejula (niraparib) full prescribing information 2022. [online]. Dostupné z: https: //www.zejulahcp.com/content/dam/cf-pharma/hcp-zejulahcp-v2/en_US/pdf/ZEJULA%20 (niraparib) %20Dear%20HCP%20Letter%20November%202022.pdf.

20. Rubraca. 2022 [online]. Dostupné z: https: //d18rn0p25nwr6d.cloudfront.net/CIK-0001466301/c27075d6-6d64-42e0-af52-a7b855dc2748.pdf.

21. Lynparza. 2023 [online]. Dostupné z: https: //www.lynparzahcp.com/content/dam/physician-services/us/590-lynparza-hcp-branded/hcp-global/pdf/solo3-dhcp-final-signed.pdf.

22. Sava J. FDA requests limited use for niraparib in patients without gBRCAm. 2022 [online]. Dostupné z: https: //www.targetedonc.com/view/fda-requests-limited-use-for-niraparib-in-patients-without-gbrcam.

23. Pujade-Lauraine E, Selle F, Scambia G et al. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial. Ann Oncol 2023; 34 (12): 1152–1164. doi: 10.1016/j.annonc.2023.09.3110.

24. Burdett NL, Willis MO, Alsop K et al. Multiomic analysis of homologous recombination-deficient end-stage high--grade serous ovarian cancer. Nat Genet 2023; 55 (3): 437–450. doi: 10.1038/s41588-023-01320-2.

25. Rose PG, Yao M, Chambers LM et al. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer. Anticancer Drugs 2021; 32 (10): 1086–1092. doi: 10.1097/CAD.0000000000001219.

26. Frenel JS, Kim JW, Aryal N et al. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Ann Oncol 2022; 33 (10): 1021–1028. doi: 10.1016/j.annonc.2022.06.011.

27. Mateo J, Lord CJ, Serra V et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 2019; 30 (9): 1437–1447. doi: 10.1093/annonc/ mdz192.

28. Mirza MR, Avall Lundqvist E, Birrer MJ et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol 2019; 20 (10): 1409–1419. doi: 10.1016/S1470-2045 (19) 30515-7.

29. Liu JF, Barry WT, Birrer M et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol 2019; 30 (4): 551–557. doi: 10.1093/annonc/mdz018.

30. Elyashiv O, Ledermann J, Parmar G et al. ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy. Int J Gynecol Cancer 2021; 31 (1): 134–138. doi: 10.1136/ijgc-2020-002073.

31. Moore KN, Bookman M, Sehouli J et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol 2021; 39 (17): 1842–1855. doi: 10.1200/JCO.21.00306.

32. Kurtz JE, Pujade-Lauraine E, Oaknin A et al. Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE/ENGOT-ov29 trial. J Clin Oncol 2023; 41 (30): 4768–4778. doi: 10.1200/JCO.23.00529.

33. Pujade-Lauraine E, Fujiwara K, Ledermann JA et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol 2021; 22 (7): 1034–1046. doi: 10.1016/S1470-2045 (21) 00216-3.

34. Powles T, Park SH, Voog E et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020; 383 (13): 1218–1230. doi: 10.1056/NEJMoa2002788.

35. Selle F, Rubio MJ, Kommoss S et al. Impact of BRCA mutation status on efficacy of atezolizumab combined with platinum-based chemotherapy and maintenance niraparib for late-relapsing recurrent ovarian cancer: subgroup analysis of the ENGOT-Ov41/GEICO 69-O/ANITA phase 3 trial. Int J Gynecol Cancer 2024; 34 (Suppl 1): A574–A575. doi: 10.1136/ijgc-2024-ESGO.1119.

36. Monk BJ, Oaknin A, O’Malley DM et al. LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC). Ann Oncol 2024; 35: S1223–S1224. doi: 10.1016/j.annonc.2024.08.2269.

37. Harter P, Trillsch F, Okamoto A et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo) -controlled phase III DUO-O trial. J Clin Oncol 2023; 41 (Suppl 17): LBA5506. doi: 10.1200/JCO.2023.41.17_suppl: LBA5506.

38. Labidi-Galy SI, Rodrigues M, Sandoval JL et al. Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. Ann Oncol 2023; 34 (2): 152–162. doi: 10.1016/j.annonc.2022.11.003.